Clinical Trial Update: Florbetaben (BAY94-9172) PET (Positron Emission Tomography) Imaging in MCI (Mild Cognitive Impairment) Patients [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating florbetaben PET imaging to detect amyloid in individuals with mild cognitive impairment or Alzheimer's disease; results were posted in …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease
• Cognitive Impairment

Drugs mentioned

• florbetaben (florbetaben)

Snippet

Sponsor: Life Molecular Imaging SA | Conditions: Alzheimer Disease, Amyloid Beta-Protein | Phase 1 | Status: COMPLETED | Results posted: 2014-06-25